Diagnostic Value of the Combined Test of Serum CA153, CA125 and CEA in Detection of Breast Cancer: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 YAOLi-yun ,  SHIGen-lin

Department of Laboratory, Jiangsu Provincial Corps Hospital, Yangzhou 225003, China;

Corresponding?author：

SHIGen-lin, Email: 2364613601@qq.com

Keywords：

Breast cancer; CA153; CA125; CEA; Systematic review; Meta-analysis; Diagnostic test

DOI：

10.7507/1672-2531.20150011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the diagnostic value of the combined test of serum CA153, CA125 and CEA in detection of breast cancer. Methods Clinical diagnostic tests about CA153, CA125 and CEA in patients with breast cancer were retrieved in PubMed, EMbase, CBM, The Cochrane Library (Issue 3, 2014), CNKI, VIP, and WanFang Data from January 1st, 2004 to April 16st, 2014. References of included literature were also retrieved. Literature screening according to the inclusion and exclusion criteria, data extraction and methodological quality assessment were completed by two reviewers independently. Meta-analysis was then conducted using Meta-Disc 1.4 software. Results A total of 21 studies involving 4 263 subjects were enrolled. In all studies, the results of meta-analysis indicated that:the DOR, AUC and Q index of the single test (CA153) were 18.71 (95%CI 11.62 to 30.11), 0.858 9, and 0.789 7; while those of the combined test (CA153, CA125 and CEA) were 37.95 (95%CI 21.97 to 65.57), 0.959 1, 0.903 1. Compared with the single test, the diagnostic efficacy of the combined test was higher (Z=3.675, P=0.001 5). Conclusion Compared with the detection of CA153 alone, the combined detection of CA125, CA153 and CEA has higher efficacy and accuracy in the diagnosis of breast cancer.

Citation： YAOLi-yun, SHIGen-lin. Diagnostic Value of the Combined Test of Serum CA153, CA125 and CEA in Detection of Breast Cancer: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2015, 15(1): 54-61. doi: 10.7507/1672-2531.20150011 Copy

1.	Jemal A, Siegel R, Xu JC, et al. Cancer statistics. CA, 2010, 60(5):277-300.
2.	Anderson BO, Shyyan R, Eniu A, et al. Breast cancer in limited-resource countries:an overview of the Breast Health Global Initiative 2005 guidelines. Breast J, 2006, 12(Suppl 1):3-15.
3.	賀延莉, 靳二虎. 乳腺癌的影像學診斷進展. 國際醫學放射學雜志, 2008, 31(4):235-239.
4.	張嘉慶, 王殊, 喬新民. 乳腺癌的現狀和遠景. 中華外科雜志, 2002, 40 (3):161-163.
5.	Park BW, Oh JW, Kim JH, et al. Preoperative CA153 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol, 2008, 19(4):675-681.
6.	Geng B, Liang MM, Ye XB, et al. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol, 2015, 3(1):232-236.
7.	Gao J, Zhang Q, Xu J, et al. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res, 2013, 25(6):743-748.
8.	易琳, 劉興明, 林丁, 等. 血清CAl53、CAl25、CEA聯合檢測在乳腺癌診斷中的價值. 重慶醫科大學學報, 2012, 37(9):802-805.
9.	張木坤, 劉露, 黃仁青, 等. 血清CAl53、CAl25和CEA聯合檢測在乳腺癌臨床診療中的應用. 國際醫藥衛生導報, 2012,18(9):1321-1323.
10.	王景萍, 洪錫田, 盛家和. 聯合檢測血清糖類抗原153、糖類抗原125、癌胚抗原在乳腺癌中的診斷價值探討. 河南醫學研究, 2007, 16(3):243-245.
11.	陳軍. CAl53、CAl25、CEA聯合檢測在乳腺癌的臨床應用. 臨床和實驗醫學雜志, 2007, 6(10):94-95.
12.	張敏, 景永. 三種腫瘤標志物聯合檢測在乳腺癌診斷中的臨床價值. 中國現代藥物應用, 2010, 4(14):48-49.
13.	韓媛媛, 李新杰, 王萍, 等. 3項腫瘤標志物檢測對乳腺癌的診斷價值. 檢驗醫學與臨床, 2012, 9(22):2859-2860.
14.	陳藝文. CAl53、CAl25及CEA聯合檢測對乳腺癌診斷的意義. 農墾醫學, 2012, 34(5):401-403.
15.	田雪玲, 秦林其, 王艷敏. 血清CA125, CA153, CEA聯合檢測在乳腺癌診斷的意義. 中國實用醫藥, 2012, (6):87-88.
16.	陳秋蕓. CA125、CA153、CEA聯合檢測在乳腺癌診斷中的臨床意義. 中國醫藥指南, 2011, 9(27):70-71.
17.	邱厚匡, 張智, 張珍, 等. 多種腫瘤標志物聯合檢測對乳腺癌診斷的臨床意義. 臨床醫學工程, 2011, 18(6):860-861.
18.	錢海英. 腫瘤標志物CAl53、CAl25、CEA聯合檢測在乳腺癌中的臨床應用. 醫學檢驗與臨床, 2008, 19(2):32-33.
19.	左新華, 周斌. CAl53、CAl25、CEA聯合檢測在乳腺癌診斷中的應用價值. 中國醫藥科學, 2011, 1(10):135-136.
20.	范柳笛. CA153、CEA、CA125 聯合檢測對乳腺癌診斷的意義研究. 臨床醫學, 2013, 26(16):102-103.
21.	練治平. CA153、CEA及CA125聯合檢測對乳腺癌診斷的意義. 國際醫藥衛生導報, 2012, 18(18):2753-2755.
22.	陳光意, 蘇金明, 呂曉嫻. CEA、CA153及CA125對乳腺癌的診斷. 中國誤診學雜志, 2005, 5(5):871-872.
23.	葉蓓, 柳光宇, 陸勁松, 等. 常用的乳腺癌血清腫瘤標志物在早期診斷中的應用價值不高. 中國癌癥雜志, 2009, 19(10):807-808.
24.	陳士華. 聯合檢測CA153、CA125、CEA對乳腺癌的臨床價值探討. 檢驗醫學, 2013, 28(3):235-237.
25.	吳愛祝, 蔡俊宏, 梁茱, 等. 血清CEA、CA125、CA153聯合檢測在乳腺癌診斷中的應用. 山東醫藥, 2011, 51(30):94-95.
26.	呂蕾, 馮雪. 血清CEA、CA125、CA153聯合檢測在乳腺癌診斷中的應用價值研究. 中國醫藥科學, 2013, 3(8):121-122.
27.	呂海軍. 血清中CA153、CA125和CEA聯合檢測對乳腺癌的診療價值探討. 中國實用醫藥, 2011, 6(33):109-110.
28.	孫麗琴. 腫瘤標記物聯合檢測乳腺癌的優越性. 航空航天醫學雜志, 2013, 24(12):1502-1503.
29.	Whiting PF, Weswood ME, Rutjes AWS, 等. QUADAS評價:一種用于診斷性研究的質量評價工具(修訂版). 中國循證醫學雜志, 2007, 7(7):531-536.
30.	張天嵩, 鐘文昭. Meta-Disc軟件在診斷試驗Meta分析中的應用. 循證醫學, 2008, 8(2):97-108.
31.	陳智周, 范振符, 楊劍. 腫瘤標志物CA153的免疫放射分析及其臨床應用. 中華腫瘤雜志, 1998, 20(2):125.
32.	Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007, 25(33):5287-5312.
33.	Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer, 1993, 71(04):1258-1265.
34.	Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 1983, 309(15):883-887.
35.	陳光意, 蘇金明, 呂曉嫻. CEA、CAl53及CAl25對乳腺癌的診斷. 中國誤診學雜志, 2005, 5(5):871-872.
36.	陳建偉, 宋建國. CAl53、CEA及CAl25聯合檢測對乳腺癌診斷的意義. 上海醫學檢驗雜志, 2000, 15(4):256.
37.	Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. J Stat Med, 2002, 21(12):1237-1256.

1. Jemal A, Siegel R, Xu JC, et al. Cancer statistics. CA, 2010, 60(5):277-300.
2. Anderson BO, Shyyan R, Eniu A, et al. Breast cancer in limited-resource countries:an overview of the Breast Health Global Initiative 2005 guidelines. Breast J, 2006, 12(Suppl 1):3-15.
3. 賀延莉, 靳二虎. 乳腺癌的影像學診斷進展. 國際醫學放射學雜志, 2008, 31(4):235-239.
4. 張嘉慶, 王殊, 喬新民. 乳腺癌的現狀和遠景. 中華外科雜志, 2002, 40 (3):161-163.
5. Park BW, Oh JW, Kim JH, et al. Preoperative CA153 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol, 2008, 19(4):675-681.
6. Geng B, Liang MM, Ye XB, et al. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol, 2015, 3(1):232-236.
7. Gao J, Zhang Q, Xu J, et al. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res, 2013, 25(6):743-748.
8. 易琳, 劉興明, 林丁, 等. 血清CAl53、CAl25、CEA聯合檢測在乳腺癌診斷中的價值. 重慶醫科大學學報, 2012, 37(9):802-805.
9. 張木坤, 劉露, 黃仁青, 等. 血清CAl53、CAl25和CEA聯合檢測在乳腺癌臨床診療中的應用. 國際醫藥衛生導報, 2012,18(9):1321-1323.
10. 王景萍, 洪錫田, 盛家和. 聯合檢測血清糖類抗原153、糖類抗原125、癌胚抗原在乳腺癌中的診斷價值探討. 河南醫學研究, 2007, 16(3):243-245.
11. 陳軍. CAl53、CAl25、CEA聯合檢測在乳腺癌的臨床應用. 臨床和實驗醫學雜志, 2007, 6(10):94-95.
12. 張敏, 景永. 三種腫瘤標志物聯合檢測在乳腺癌診斷中的臨床價值. 中國現代藥物應用, 2010, 4(14):48-49.
13. 韓媛媛, 李新杰, 王萍, 等. 3項腫瘤標志物檢測對乳腺癌的診斷價值. 檢驗醫學與臨床, 2012, 9(22):2859-2860.
14. 陳藝文. CAl53、CAl25及CEA聯合檢測對乳腺癌診斷的意義. 農墾醫學, 2012, 34(5):401-403.
15. 田雪玲, 秦林其, 王艷敏. 血清CA125, CA153, CEA聯合檢測在乳腺癌診斷的意義. 中國實用醫藥, 2012, (6):87-88.
16. 陳秋蕓. CA125、CA153、CEA聯合檢測在乳腺癌診斷中的臨床意義. 中國醫藥指南, 2011, 9(27):70-71.
17. 邱厚匡, 張智, 張珍, 等. 多種腫瘤標志物聯合檢測對乳腺癌診斷的臨床意義. 臨床醫學工程, 2011, 18(6):860-861.
18. 錢海英. 腫瘤標志物CAl53、CAl25、CEA聯合檢測在乳腺癌中的臨床應用. 醫學檢驗與臨床, 2008, 19(2):32-33.
19. 左新華, 周斌. CAl53、CAl25、CEA聯合檢測在乳腺癌診斷中的應用價值. 中國醫藥科學, 2011, 1(10):135-136.
20. 范柳笛. CA153、CEA、CA125 聯合檢測對乳腺癌診斷的意義研究. 臨床醫學, 2013, 26(16):102-103.
21. 練治平. CA153、CEA及CA125聯合檢測對乳腺癌診斷的意義. 國際醫藥衛生導報, 2012, 18(18):2753-2755.
22. 陳光意, 蘇金明, 呂曉嫻. CEA、CA153及CA125對乳腺癌的診斷. 中國誤診學雜志, 2005, 5(5):871-872.
23. 葉蓓, 柳光宇, 陸勁松, 等. 常用的乳腺癌血清腫瘤標志物在早期診斷中的應用價值不高. 中國癌癥雜志, 2009, 19(10):807-808.
24. 陳士華. 聯合檢測CA153、CA125、CEA對乳腺癌的臨床價值探討. 檢驗醫學, 2013, 28(3):235-237.
25. 吳愛祝, 蔡俊宏, 梁茱, 等. 血清CEA、CA125、CA153聯合檢測在乳腺癌診斷中的應用. 山東醫藥, 2011, 51(30):94-95.
26. 呂蕾, 馮雪. 血清CEA、CA125、CA153聯合檢測在乳腺癌診斷中的應用價值研究. 中國醫藥科學, 2013, 3(8):121-122.
27. 呂海軍. 血清中CA153、CA125和CEA聯合檢測對乳腺癌的診療價值探討. 中國實用醫藥, 2011, 6(33):109-110.
28. 孫麗琴. 腫瘤標記物聯合檢測乳腺癌的優越性. 航空航天醫學雜志, 2013, 24(12):1502-1503.
29. Whiting PF, Weswood ME, Rutjes AWS, 等. QUADAS評價:一種用于診斷性研究的質量評價工具(修訂版). 中國循證醫學雜志, 2007, 7(7):531-536.
30. 張天嵩, 鐘文昭. Meta-Disc軟件在診斷試驗Meta分析中的應用. 循證醫學, 2008, 8(2):97-108.
31. 陳智周, 范振符, 楊劍. 腫瘤標志物CA153的免疫放射分析及其臨床應用. 中華腫瘤雜志, 1998, 20(2):125.
32. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007, 25(33):5287-5312.
33. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer, 1993, 71(04):1258-1265.
34. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 1983, 309(15):883-887.
35. 陳光意, 蘇金明, 呂曉嫻. CEA、CAl53及CAl25對乳腺癌的診斷. 中國誤診學雜志, 2005, 5(5):871-872.
36. 陳建偉, 宋建國. CAl53、CEA及CAl25聯合檢測對乳腺癌診斷的意義. 上海醫學檢驗雜志, 2000, 15(4):256.
37. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. J Stat Med, 2002, 21(12):1237-1256.

Previous Article
Safety and Immunogenicity of Quadrivalent HPV Vaccine: A Meta-analysis
Next Article
Non-depolarizing Neuromuscular Blockers for Prevention of Succinylcholine-induced Myalgia: A Meta-analysis

Chinese Journal of Evidence-Based Medicine

Diagnostic Value of the Combined Test of Serum CA153, CA125 and CEA in Detection of Breast Cancer: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content